Vaccine To Be Priced As Per Country’s GDP: Pfizer
New York: Pfizer has decided to keep a differential pricing on its COVID-19 vaccine, which will be based on a country’s GDP.
CEO Albert Bourla has said the vaccine will have tiered pricing in middle-income countries like India, while it will be free in Africa.
In the US, the cost is $19.50, the price of an average meal there, Bourla noted.
The vaccine was approved by the UK on December 2. It has applied for approval in India where it normally takes up to 90 days to decide.
India has the world’s second-highest number of cases at 97.35 lakh after the United States.
The Pfizer vaccine needs to be stored at minus 70 degrees Celsius, a challenge for countries like India.
Comments are closed.